Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

the 31 patients with stable disease or better, one

patient had a complete response and four patients had partial

responses (two unconfirmed).

-- SNS-595 has been generally well tolerated in this trial, with a low

rate of febrile neutropenia or other Grade 3/4 adverse events and

manageable Grade 1/2 nausea or vomiting. Based on the drug's

observed safety profile and indications of clinical activity,

Sunesis amended the protocol to explore a higher dose of SNS-595 in

this trial. Enrollment has begun at a dose of 60 mg/m2 over twenty-

eight days, and Sunesis anticipates enrolling approximately 30

patients at this dose in the third quarter of this year.

-- Data from this trial has been accepted for presentation at the 44th

ASCO Annual Meeting.

-- Sunesis updated the results from the company's Phase 1 clinical trial

of single-agent SNS-595 in patients with relapsed or refractory acute

leukemias, which had previously been reported at the 49th Annual

Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia

in December 2007. Since the ASH presentation, an additional patient in

this trial has achieved a complete remission.

-- Twelve of 30 patients (43 percent) who received doses of SNS-595 of

50 mg/m2 or greater on a weekly dose schedule have now achieved bone

marrow blast reductions to less than five percent, and five of these

12 patients achieved either complete remission, complete remission

without platelet recovery or complete remission with incomplete

recovery of normal hematopoietic blood elements.

-- SNS-595 was generally well tolerated in this trial, with a

dose-limiting toxicity of reversible Grade 3/4 oral mucositis.

-- Based on these promising results, Sunesis
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Continuing its award-winning streak, Nerium International, ... MarCom Awards for outstanding creative achievement by its marketing ... Award, the organization’s top honor, in the Branding category ... in April of this year. The event showcased top ... Nerium was awarded a Gold MarCom Award in the ...
(Date:11/26/2014)... WILMINGTON, DE (PRWEB) November 26, 2014 ... MPN Heroes recognition reception on December 5, 2014, in ... annual meeting. The MPN Heroes event will honor clinicians, ... the field of myeloproliferative neoplasms (MPNs). , Special ... will discuss his family's cancer journey at the reception. ...
(Date:11/26/2014)... WARREN, N.J. , Nov. 25, 2014  Roka Bioscience, ... focused on providing advanced testing solutions for the detection of ... will present at the Piper Jaffray  26 th Annual ... conference will be held at The New York Palace in ... During this presentation, material information concerning the Company, its operations, ...
(Date:11/24/2014)...   First published ... Elsevier , a world-leading provider of scientific, technical ... the launch of the latest title in the Current ... Food Science . Current ... new platform to keep up-to-date with the expanding volume of ...
Breaking Biology Technology:Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 3
... BioCryst,Pharmaceuticals, Inc. (Nasdaq: BCRX ) today ... Life Sciences Conference in New York. A live ... 2007 at 2:00 p.m. Eastern,Time may be accessed ... will be archived for seven days. (Logo: ...
... September 24 ThalesNano Inc., a,leading developer ... and hydrogenation technology solutions, announced today that ... a subsidiary in the United,Kingdom and by ... Building its own subsidiary reflects ThalesNano,s ...
... (Nasdaq and MTAX: CTIC) today announced that Richard L. ... Chairman of the Board for,Systems Medicine, which was recently ... Genomics Institute ("TGen") in Arizona,uses the latest drug development ... and identify which drugs will be most effective,at treating ...
Cached Biology Technology:BioCryst to Present at UBS 2007 Global Life Sciences Conference 2BioCryst to Present at UBS 2007 Global Life Sciences Conference 3ThalesNano Inc. Opens Own Representation in the United Kingdom and has New Distribution Agreements for Europe and India 2Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI) 2Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI) 3
(Date:11/21/2014)... , Nov. 20, 2014 Strict laws against ... are piloting the North American and European automotive sector ... growing, gesture recognition systems that are intuitive and able ... in the industry. New analysis from ... Recognition Market in Europe and ...
(Date:11/18/2014)... , Nov. 17, 2014 The Parenteral Drug ... U.S. regulatory agencies will speak and at least seven more ... Conference at the Omni Shoreham Hotel in Washington ... once again to have significant support from the regulatory agencies ... Europe in our effort to help advance ...
(Date:11/10/2014)... detergent pods began appearing on U.S. store shelves in ... numbers ever since. The small packets can be tossed ... out a liquid or powder. The convenience, though, has ... study from researchers at Nationwide Children,s Hospital found that ... reports of 17,230 children younger than 6 years of ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Study finds laundry detergent pods, serious poisoning risk for children 2
... 2010 Scientists studying the environmental impact of Hurricane ... city of New Orleans have revealed the ecological impact ... The findings, published in a special issue of ... caused significant ecological damage by altering coastal chemistry and ...
... exposure to ionizing radiation can result in mutations or ... Now a new study led by researchers with the ... Lab) has revealed another way in which radiation can ... cells, the researchers discovered that radiation exposure can alter ...
... invasive aquatic organism that is on the state,s most ... Bay and Coos Bay, and scientists say this "colonial ... economic and environmental implications. Its propensity to foul ... buoys could make it costly to control, and its ...
Cached Biology News:New research reveals Hurricane Katrina's impact on ecological and human health 2New research reveals Hurricane Katrina's impact on ecological and human health 3Study raises new concerns about radiation and breast cancer 2Study raises new concerns about radiation and breast cancer 3Invasive 'tunicate' appears in Oregon's coastal waters 2Invasive 'tunicate' appears in Oregon's coastal waters 3Invasive 'tunicate' appears in Oregon's coastal waters 4
... Ribonuclease Inhibitors have broad spectrum RNase inhibitory ... of the neutral type (1). The 50kDa ... binding to RNases in a 1:1 ratio. ... RNasin Ribonuclease Inhibitor to RNase (e.g., RNase ...
UGT1A7 (E-15)...
... corresponding to the third cytoplasmic loop of ... to KLH. The immunizing peptide has 79% ... Physical form: Solution in phosphate buffered ... Titertest method: IHC (p). Titertest ...
... Human Pathogenic Viruses The ... (NCPV) preserves well characterised, authenticated ... secure facility, and NCPV is ... or nucleic acids derived from ...
Biology Products: